Remove tag sales-engagement
article thumbnail

STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more

STAT

As for us, we are engaged in the usual ritual of brewing cups of stimulation. Department of Justice is conducting a criminal investigation into the McKinsey consulting firm over its past role in advising some of the nation’s largest opioid manufacturers on how to boost sales , The Wall Street Journal reports.

Packaging 102
article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Engagement channels. Virtual connections. Joanna Carlish.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top Commercial Benefits of Modular Approach

Viseven

Omnichannel allows to both cover the whole customer’s perspective on the internet, reaching out to him wherever it is comfortable for them across channels, and provide them with an engaging experience, being flexible with content and message delivery from channel to channel. How to calculate cost efficiency? Communication quality and agility.

article thumbnail

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes. It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. ” Image by Pexels from Pixabay .

article thumbnail

Orphan drugs’ financial success raises questions

pharmaphorum

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. By 2026, this would mean that orphan drug sales will account for 20% of all prescription drug sales. Raising questions.

article thumbnail

Biogen updates on its confirmatory Aduhelm trial

pharmaphorum

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52
article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

This gives them huge amounts of customer data that allows them to shape and personalise the way they engage with their customers, not least thanks to the direct-to-consumer sales model they often offer. Jeremy Richter, Tag. Build on the rapid responses to COVID-19.